Idexx Laboratories (IDXX) has been identified as a compelling growth stock by Zacks, meriting a Growth Score of B and a Zacks Rank #2. This designation is underpinned by a projected 14.1% EPS growth for the current year, exceeding the industry average, and a robust 6% year-over-year cash flow growth, significantly outperforming peers. Furthermore, recent upward revisions to current-year earnings estimates reinforce IDXX's position as a potential outperformer for growth-oriented investors.
Idexx Laboratories (IDXX) presents a compelling growth case based on strong fundamental indicators and positive analyst sentiment. The company is projected to deliver 14.1% EPS growth for the current year, a figure that not only represents an acceleration from its historical 12.5% rate but also modestly exceeds the industry's average forecast of 13.6%. This earnings strength is substantially supported by robust cash generation; IDXX reports 6% year-over-year cash flow growth, which is a significant outperformance compared to the industry average of -0.8%. This trend of superior cash flow is a long-term characteristic, with its 3-5 year annualized rate of 14.6% more than doubling the industry's 6.7%. Further reinforcing the positive outlook, consensus earnings estimates for the current year have been revised upward by 0.1% over the last month, a metric empirically linked to near-term stock appreciation. This combination of above-average earnings growth, superior cash flow dynamics, and positive estimate revisions underpins its Zacks Rank #2 (Buy) and Growth Score of B.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment